CBCE - Activity Details

Fourth Annual Multidisciplinary Interactive Thoracic Oncology Conference

Seattle, Washington
April 11 - 12, 2008

Statement of Need
Despite several decades of extensive research, the median survival for patients with non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) is approximately 1 year. In 2007, 160,390 deaths from cancer of the lung and bronchus are expected to occur, accounting for 29% of all cancer deaths. Over the last several decades, a variety of treatment approaches, including combinations of available chemotherapy drugs and multimodality therapies, have demonstrated only modest efficacy in improving patient quality of life or survival. Moving forward, a 3-fold approach to generating clinical improvements in the treatment of thoracic malignancies has evolved: better disease characterization, novel therapeutics including targeted agents and radiation-delivery techniques, and optimized scheduling of multimodality therapies. New research has led to steady advancements in recent years, including the development of novel targeted and chemotherapeutic agents, enhanced approaches to standard treatments (such as novel radiation regimens and multimodality therapies), and improvements in the adjuvant setting. This conference will focus on the latest advances in diagnosis and treatment of patients with NSCLC or SCLC, including surgical, chemotherapeutic, and biologic strategies. In addition, the conference will emphasize novel therapies and techniques currently undergoing development and will evaluate the optimization of these techniques for today’s clinical practice.

Target Audience
This activity is designed for lung cancer specialists, medical oncologists, radiation oncologists, surgical oncologists, thoracic surgeons, nurses, pharmacists, advanced practitioners, physician assistants, and other health care professionals involved in the treatment of patients with thoracic malignancies.

Educational Objectives
After participating in this educational activity, attendees should be able to:

Describe the standard care of patients with early-stage NSCLC, and discuss recent trials incorporating adjuvant and/or neoadjuvant chemotherapy into treatment regimens for patients eligible for surgery.
Evaluate current clinical trial data addressing the safety and efficacy of various chemoradiotherapeutic regimens in the treatment of patients with locally advanced NSCLC.
Compare treatment options for elderly patients with NSCLC, taking into consideration patient comorbidities, performance status, and adverse responses to systemic therapy.
Assess the results from recent studies aimed at identifying markers and patient characteristics that are predictive of response to specific EGFR inhibitors.
Assess key clinical considerations when selecting a patient to receive antiangiogenic therapy.
Summarize alternative or additional treatment approaches, such as maintenance therapy and PCI, which may potentially lead to improved clinical outcomes for patients with NSCLC.
Evaluate the results of recent studies investigating therapy options for the treatment of SCLC.

Method of Participation
Audience Response System, case studies, lectures, visual aids, presentations, and discussion will be utilized to engage attendees and enhance the learning process. All attendees will receive a comprehensive CD-ROM of the program presentations approximately 4-6 weeks after the conference.

Accreditation
Physicians: The CBCE™ (The Center for Biomedical Continuing Education) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the Essential Areas and policies of the ACCME.

The CBCE designates this educational activity for a maximum of 8.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in this activity.

Physician Assistants: AAPA accepts category 1 credit from AOACCME, prescribed credit from AAFP, and AMA category 1 CME credit for the PRA from organizations accredited by the ACCME.

Nurses: The CBCE™ (The Center for Biomedical Continuing Education) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The CBCE designates this educational activity for 8.25 contact hours. Accreditation by the American Nurses Credentialing Center's Commission on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.

Pharmacists: The CBCE™ (The Center for Biomedical Continuing Education) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
CPE Credit: 8.25 contact hours or 0.825 CEUs
Universal Program Number: 195-000-07-022-L01-P

Acknowledgement of Commercial Support

The CBCE gratefully acknowledges the educational grants provided by:

Genentech BioOncology/OSI Oncology

Eli Lilly and Company
sanofi-aventis

AstraZeneca Pharmaceuticals LP./Abraxis BioScience, Inc.
Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals, Inc.
Merck & Co., Inc.

Certificate
The Evaluation and Request for Credit Form must be completed and returned to the CBCE following this activity to obtain credit. Participants will receive their certificate 4-6 weeks after the CBCE receives their form.

Americans With Disabilities Act (ADA)
The CBCE fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of support services, please notify the CBCE staff at the conference registration desk in order to receive service.

Educational Inquiries
For further information, please contact the CBCE, 1707 Market Place Blvd., Suite 370, Irving, Texas 75063; Telephone: (214) 260-9024; Fax: (214) 260-0509; E-mail: info@thecbce.com.

Chair(s)

Vivek K. Mehta, MD
Director, Center for Advanced Targeted Radiotherapy, Department of Radiation Oncology
Swedish Cancer Institute

Eric Vallières, MD, FRCSC
Surgical Director, Lung Cancer Program
Swedish Cancer Institute

H. Jack West, MD
Medical Director, Thoracic Oncology Program
Swedish Cancer Institute

Faculty

Julie R. Brahmer, MD
Assistant Professor
Johns Hopkins University

David R. Gandara, MD
Professor of Medicine, Division of Hematology/Oncology
Associate Director of Clinical Research, Director, Thoracic Oncology
UC Davis Cancer Center

Laurie Gaspar, MD, MBA, FACR
Professor and Chair
University of Colorado at Denver and Health Sciences Center

Jed Gorden, MD
Director, Interventional Pulmonology
Minor & James Medical, PLLC
Swedish Cancer Institute

Ramaswamy Govindan, MD
Associate Professor of Medicine
Washington University

David M. Jablons, MD
Professor and Chief
University of California, San Francisco

Edward S. Kim, MD
Assistant Professor of Medicine
The University of Texas M. D. Anderson Cancer Center

Tarek Mekhail Sr, MD
Hardis Chair in Oncology Research
Cleveland Clinic

Daniel L. Miller, MD
Kamal A. Mansour Professor of Surgery, Chief, General Thoracic Surgery
Emory University School of Medicine

Suresh Ramalingam, MD
Chief of Thoracic Medical Oncology
Emory Winship Cancer Institute

Gregory Videtic, MD
Department of Radiation Oncology
Cleveland Clinic

Heather Wakelee, MD
Assistant Professor of Medicine, Oncology
Stanford University School of Medicine, Stanford Comprehensive Cancer Center

Thomas J. Watson, MD
Associate Professor & Chief of Thoracic Surgery
University of Rochester Medical Center

Friday, April 11 2008

Case 1: Borderline Resectable Elderly
Case 2: Residual Viable Tumor in the Radiation Field of a Good PS Woman After Chemotherapy/RT
Case 4: Extensive-Disease SCLC in a Good PS Patient
Case 3: Locally Advanced NSCLC in an 81-Year-Old Never-Smoker
11:30 AM - 12:30 PM	Registration and Lunch
12:30 - 12:40 PM	Welcome and Introductions	H. Jack West, MD
12:40 - 1:00 PM	Resection in Elderly or Marginal Lung Function	Daniel L. Miller, MD
1:00 - 1:20 PM	New Developments in Neoadjuvant and Adjuvant Therapy for NSCLC	Heather Wakelee, MD
1:20 - 1:40 PM	Panel Discussion and ARS Questions
1:40 - 1:55 PM	Evolving Standards in Chemoradiation for Unresectable Stage III NSCLC	Ramaswamy Govindan, MD
1:55 - 2:10 PM	Salvage Local Therapies for Local Failures After Chemoradiation: Surgery	David M. Jablons, MD
2:10 - 2:25 PM	Salvage Local Therapies for Local Failures After Chemoradiation: Stereotactic RT	Vivek K. Mehta, MD
2:25 - 2:40 PM	Panel Discussion and ARS Questions
2:40 - 3:00 PM	Break
3:00 - 3:15 PM	RT Options in Elderly/Poor Performance Status Patients	Laurie Gaspar, MD, MBA, FACR
3:15 - 3:30 PM	Current State of the Art for Molecular Predictors of Benefit With EGFR-Based Therapies	David R. Gandara, MD
3:30 - 3:45 PM	Optimizing Lung Function in Marginal Candidates for Curative Therapy	Jed Gorden, MD
3:45 - 4:00 PM	Panel Discussion and ARS Questions
4:00 - 4:20 PM	New Data and Changing Standards of Care in SCLC	Tarek Mekhail Sr, MD
4:20 - 4:40 PM	Treatment Options in the Recurrent Disease Setting: Present and Future	Suresh Ramalingam, MD
4:40 - 5:00 PM	Panel Discussion and ARS Questions
7:00 - 10:00 PM	Dinner

Saturday, April 12 2008

Case 5: Solitary Brain Metastasis in 54-Year-Old Man With Good Performance Status
Case 6: Thymoma Case: 63-Year-Old Male, Good PS, Large-10 cm Thymic Mass, No Myasthenia Gravis
Case 7: Pancoast Tumor, Borderline Resectability
8:00 - 9:15 AM	Interesting (Weird and Unusual) Cases in Lung Cancer Surgery	Surgical Oncologists
8:00 - 9:15 AM	4D Treatment Planning/Adaptive RT Protocol Discussion	Radiation Oncologists
8:00 - 9:15 AM	Case: New Diagnosis of Advanced NSCLC in 73-Year-Old Woman Who Is a Debatable Candidate for Bevacizumab	Medical Oncologists
8:00 - 8:25 AM	Refining First-Line Treatment Options in 2008: Bevacizumab and Beyond	Julie R. Brahmer, MD
8:25 - 8:45 AM	Second-Line Therapy: Timing and Treatment Choices	Edward S. Kim, MD
8:45 - 9:15 AM	Panel Discussion and ARS Questions
9:15 - 9:30 AM	Break
9:30 - 9:50 AM	The Precocious Metastasis and Potential for “Curing” Stage IV NSCLC	Thomas J. Watson, MD
9:50 - 10:10 AM	RT for Brain Metastases: Current Indications for Whole-Brain vs Stereotactic Radiosurgery	Gregory Videtic, MD
10:10 - 10:30 AM	Panel Discussion and ARS Questions
10:30 - 10:50 AM	Borderline Resectable Thymoma, the Role for Induction Therapy	Thomas J. Watson, MD
10:50 - 11:10 AM	Rationale and Timing for Radiotherapy in the Management of Thymoma: Resected and Unresected Disease	Gregory Videtic, MD
11:10 - 11:30 AM	Panel Discussion and ARS Questions
11:30 - 11:50 AM	Current Data and Management Options for Pancoast Tumors	Daniel L. Miller, MD
11:50 AM - 12:15 PM	Panel Discussion and ARS Questions
12:15 - 12:30 PM	Closing Comments, Evaluations, and Adjournment	Eric Vallières, MD, FRCSC

Seattle, Washington

Bell Harbor International Conference Center

2211 Alaskan Way, Pier 66
Seattle, WA 98121
www.bellharbor.com

Accommodations available at
The Edgewater Hotel
2411 Alaskan Way, Pier 67
Seattle, WA 98121

www.edgewaterhotel.com

Group Rate
Room accommodations for this conference are $225 per night, single or double occupancy, with an approximate 15.6% tax.

There will be an additional charge of $20 per day for each additional person over the age of 18. The maximum number of people per guest room is 4. A maximum of 2 children under the age of 18 per room are complimentary.

Reservation Guarantee
An early response is suggested for guests desiring the group rate. To ensure the group rate, reservations must be made through the CBCE by Tuesday, March 11, 2008. After March 11, 2008, no guarantee is provided for accommodation availability or our room rate at the Edgewater Hotel. Room type and group room rate are subject to availability. Check-in time is 4:00 pm; check-out time is 12:00 pm. All reservations must be guaranteed with a 1-night room deposit or a major credit card. A credit card is necessary to guarantee a late arrival. All major credit cards are accepted by the Edgewater Hotel.

Hotel Cancellation Policy
No-shows will be charged the full amount of the reservation. Any guaranteed rooms cancelled less than 14 days prior to the day of arrival will be charged the 1-night deposit amount. If the hotel is able to resell the reservation, you will not be charged the cancellation fee.

Climate
The climate in Seattle, Washington, in April is cool with temperatures ranging from an average daily low of 42°F to an average daily high of 58°F. A light jacket is recommended.

Limousine and Rental Car Services
Reservations can be made through the Edgewater Hotel concierge by calling (206) 728-7000, ext. 292.

Parking
Valet parking is available at the Edgewater Hotel for $5/hour, and overnight parking is $24 plus tax.

Taxi
If you wish to take a taxi to the Edgewater Hotel, expect a fare of approximately $35 from Sea-Tac Airport.

Conference Cancellation Policy
If a cancellation notice is received in writing by March 11, 2008, 75% of the registration fee will be refunded. All cancellation requests should be sent to the CBCE at the address on the next page.